Is annualised eGFR change associated with reductions in clinical heart failure events with GLP-1 receptor agonists?
Patients in large-scale GLP-1 receptor agonist randomised controlled trials
GLP-1 receptor agonists
Clinical heart failure events and annualised eGFR change
Annualised eGFR change may serve as a useful marker of heart failure benefit with GLP-1 receptor agonists.
Across large-scale GLP-1RA trials, greater annualised eGFR improvement was associated with larger reductions in clinical HF events. Annualised eGFR change may serve as a useful marker of HF benefit with GLP-1RAs.
Building similarity graph...
Analyzing shared references across papers
Loading...
Masashi Hasebe
Hisashi Kamido
Chen‐Yang Su
Diabetes Obesity and Metabolism
McGill University
Kyoto University
McGill University and Génome Québec Innovation Centre
Building similarity graph...
Analyzing shared references across papers
Loading...
Hasebe et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69df2abce4eeef8a2a6afcd0 — DOI: https://doi.org/10.1111/dom.70749
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: